* MannKind Corp MNKD.OQ reported quarterly adjusted
earnings of
5 cents per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of 1 cents. The mean expectation of four analysts for the
quarter was for earnings of 3 cents per share. Wall Street
expected results to range from 2 cents to 4 cents per share.
* Revenue fell 61.5% to $19.73 million from a year ago;
analysts
expected $74.50 million.
* MannKind Corp's reported EPS for the quarter was 4 cents.
* The company reported quarterly net income of $11.55
million.
* MannKind Corp shares had risen by 17.5% this quarter and
gained 103.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 20% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for MannKind Corp is
$9.00
This summary was machine generated from LSEG data November 8 at
05:24 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.03 0.05 Beat
Jun. 30 2024 0.01 -0.01 Missed
Mar. 31 2024 0.03 0.04 Beat
Dec. 31 2023 0.00 0.00 Met